selegiline

(redirected from Anipryl)
Also found in: Dictionary, Wikipedia.

selegiline

 [sĕ-lej´ĭ-lēn]
an agent used in treatment of parkinsonism; used as the hydrochloride salt in conjunction with levodopa and carbidopa.

selegiline

/se·le·gil·ine/ (sĕ-lej´ĭ-lēn) an antiparkinsonian agent used as the hydrochloride salt in conjunction with levodopa and carbidopa.

selegiline

(sə-lĕj′ə-lēn′)
n.
A selective monoamine oxidase inhibitor, C13H17N, used transdermally as an antidepressant and in its hydrochloride form in conjunction with levodopa and carbidopa to treat patients with Parkinson's disease.

deprenyl

Alternative pharmacology
A prescription drug used to treat Parkinson’s disease, which has acquired currency among some practitioners of alternative medicine as an anti-ageing substance; deprenyl acts on the substantia nigra., a region of the brain that is believed to age more rapidly than others, by blocking the degradation of dopaminergic neurotransmitters.

selegiline

l-Deprenyl Neuropharmacology A selective monoamine oxidase type B inhibitor which, with l-dopa, may be useful for early symptomatic treatment of parkinsonism

selegiline

A selective MONOAMINE OXIDASE INHIBITOR drug used in the treatment of PARKINSONISM. Selegiline is thought to retard the breakdown of DOPAMINE. Brand names are Eldepryl and Vivapril.

selegiline (seˑ·l·gi·lēnˈ),

n an MAO-B inhibitor used to treat Parkinson's disease. It also acts as an antioxidant and an immunostimulant, protects nerve tissue from degeneration, and has positive effects on cognition. Also called
deprenyl or
l-deprenyl.
References in periodicals archive ?
Anipryl has Food and Drug Administration (FDA) clearance in the U.
Under the agreement, Pfizer will support Draxis in expanding research and development into new indications and formulations of Anipryl.
Anipryl was approved and is currently being sold in Canada for the same indication.
Anipryl was found to successfully treat the disorder including both the symptoms and the abnormal chemistry in over 75% of cases.
Anipryl has also shown effectiveness in canine cognitive dysfunction, a much more prevalent disorder in older dogs.
DAHI) (OTC-BB: DAHI; Toronto Stock Exchange: DAH) filed for Canadian regulatory approval to market Anipryl, to treat canine cognitive dysfunction, an Alzheimer's-like disease in geriatric dogs.
Financial results for the fourth quarter of 1996 are expected to improve over the third quarter as the investments associated with the initial market introductions of Anipryl and Kerasal are now substantially complete and these products, as well as the Tican products, begin to make positive contributions.
The outlook for the next 12 months remains positive with the prospect of the launch of Anipryl in the U.
distribution during the quarter of Anipryl, the veterinary
holds Canadian rights for all indications for Anipryl in Canada.
second indication for Anipryl in Canada -- as a treatment for canine
Manufacturing revenues have been reclassified for accounting purposes, and now include both DRAXIS Pharma sales as well as Anipryl (R) product sales to Pfizer.